Drug intelligence / Profile preview

vabametkib + lazertinib

Development stage: Unknown
Lead developer: Abion
Modality: Small Molecules
Administration: Oral

Overview

**Vabametkib + lazertinib** is an investigational oral combination therapy targeting advanced non-small cell lung cancer (NSCLC) patients who have developed resistance to epidermal growth factor receptor (EGFR)-targeted therapies, usually due to c-MET overexpression or amplification. Vabametkib (ABN401) is a potent, selective MET (hepatocyte growth factor receptor) inhibitor, while lazertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI). This combination is being evaluated for efficacy and safety in Phase 2 clinical trials, with the primary aim of overcoming acquired resistance in EGFR-mutant NSCLC[1][3][7].

Other names: vabametkib + lazertinib

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)MET (Mesenchymal-epithelial transition factor receptor)

Beyond the preview

Go deeper on vabametkib + lazertinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on vabametkib + lazertinib.

Explore the full profile